KR100710100B1
(ko)
|
1999-04-15 |
2007-04-23 |
브리스톨-마이어스스퀴브컴파니 |
환형 단백질 티로신 키나제 억제제
|
EP1671969A3
(en)
*
|
2000-12-21 |
2006-07-26 |
Bristol-Myers Squibb Company |
Thiazolyl inhibitors of tec family tyrosine kinases
|
KR100847169B1
(ko)
|
2000-12-21 |
2008-07-17 |
글락소 그룹 리미티드 |
혈관형성 조절제로서의 피리미딘아민
|
ATE318812T1
(de)
|
2000-12-21 |
2006-03-15 |
Bristol Myers Squibb Co |
Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
|
CA2436487A1
(en)
*
|
2001-01-30 |
2002-08-08 |
Cytopia Pty Ltd. |
Methods of inhibiting kinases
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
JP2004536057A
(ja)
|
2001-05-11 |
2004-12-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
p38インヒビターとして使用する2,5−二置換ピリジン、ピリミジン、ピリダジンおよび1,2,4−トリアジンの誘導体
|
EP1397142A4
(en)
|
2001-06-19 |
2004-11-03 |
Bristol Myers Squibb Co |
PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
|
AU2002346053B2
(en)
*
|
2001-06-22 |
2008-03-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
DE10133665A1
(de)
*
|
2001-07-11 |
2003-01-30 |
Boehringer Ingelheim Pharma |
Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
|
WO2003015778A1
(en)
|
2001-08-17 |
2003-02-27 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
KR20040066788A
(ko)
|
2001-08-31 |
2004-07-27 |
더 락커펠러 유니버시티 |
프스포다이에스터레이즈 활성 및 뇌에서프스포다이에스터레이즈 1b 매개되는 신호의 조절
|
WO2003027295A2
(en)
*
|
2001-09-24 |
2003-04-03 |
University Of Aarhus |
Methods for diagnosis and treatment of diseases associated with altered expression of jak1
|
WO2003062215A1
(en)
*
|
2002-01-25 |
2003-07-31 |
Kylix Pharmaceuticals B.V. |
4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
|
US20040014744A1
(en)
*
|
2002-04-05 |
2004-01-22 |
Fortuna Haviv |
Substituted pyridines having antiangiogenic activity
|
AU2003241326B2
(en)
|
2002-05-02 |
2008-05-01 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
NZ537155A
(en)
*
|
2002-05-23 |
2006-09-29 |
Cytopia Pty Ltd |
Protein kinase inhibitors
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
US20040023981A1
(en)
*
|
2002-07-24 |
2004-02-05 |
Yu Ren |
Salt forms with tyrosine kinase activity
|
US20040023978A1
(en)
*
|
2002-07-24 |
2004-02-05 |
Yu Ren |
Active salt forms with tyrosine kinase activity
|
NZ540161A
(en)
*
|
2002-10-30 |
2008-03-28 |
Vertex Pharma |
Compositions useful as inhibitors of rock and other protein kinases
|
AU2002953255A0
(en)
*
|
2002-12-11 |
2003-01-02 |
Cytopia Research Pty Ltd |
Protein kinase inhibitors
|
GB0305152D0
(en)
*
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
GB2400101A
(en)
*
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
TW200519106A
(en)
|
2003-05-02 |
2005-06-16 |
Novartis Ag |
Organic compounds
|
WO2005000208A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Combinatorx, Inc. |
Combination therapy for the treatment of neoplasms
|
WO2005003101A2
(en)
*
|
2003-07-02 |
2005-01-13 |
Biofocus Discovery Limited |
Pyrazine and pyridine derivatives as rho kinase inhibitors
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
GB0320197D0
(en)
|
2003-08-28 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
CN102127056B
(zh)
|
2003-12-03 |
2013-08-21 |
Ym生物科学澳大利亚私人有限公司 |
微管蛋白抑制剂
|
US7294640B2
(en)
|
2004-02-06 |
2007-11-13 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
CA2567569A1
(en)
|
2004-05-21 |
2006-01-26 |
Banyu Pharmaceutical Co., Ltd. |
Selective inhibitors against cdk4 and cdk6 having aminothiazole skeleton
|
EA011671B1
(ru)
*
|
2004-06-04 |
2009-04-28 |
Арена Фармасьютикалз, Инк. |
Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
|
US7491720B2
(en)
|
2004-10-29 |
2009-02-17 |
Banyu Pharmaceutical Co., Ltd. |
Aminopyridine derivatives having Aurora A selective inhibitory action
|
MX2007005155A
(es)
*
|
2004-10-29 |
2007-06-26 |
Banyu Pharma Co Ltd |
Nuevos derivados de aminopiridina que tienen accion inhibidora selectiva de la aurora a.
|
CA2585490A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Galapagos Nv |
Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
|
GB0428082D0
(en)
*
|
2004-12-22 |
2005-01-26 |
Welcome Trust The Ltd |
Therapeutic compounds
|
SI2383268T1
(sl)
|
2005-02-04 |
2016-02-29 |
Astrazeneca Ab |
Derivati pirazolilaminopiridina uporabni kot kinazni inhibitorji
|
DK1853588T3
(da)
|
2005-02-16 |
2008-09-15 |
Astrazeneca Ab |
Kemiske forbindelser
|
EP1899323A2
(en)
|
2005-05-16 |
2008-03-19 |
AstraZeneca AB |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
MX2007014886A
(es)
*
|
2005-05-24 |
2008-02-19 |
Serono Lab |
Derivados de tiazol y uso de los mismos.
|
WO2006129842A1
(ja)
*
|
2005-06-01 |
2006-12-07 |
Banyu Pharmaceutical Co., Ltd. |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
JP5084725B2
(ja)
|
2005-06-06 |
2012-11-28 |
武田薬品工業株式会社 |
有機化合物
|
AU2006258101A1
(en)
*
|
2005-06-09 |
2006-12-21 |
Merck Sharp & Dohme Corp. |
Inhibitors of checkpoint kinases
|
JP2009503073A
(ja)
*
|
2005-08-02 |
2009-01-29 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
タンパク質キナーゼ阻害剤としての5−置換チアゾール−2−イルアミノ化合物および組成物
|
EP1919287A4
(en)
*
|
2005-08-23 |
2010-04-28 |
Intra Cellular Therapies Inc |
ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
|
PL1945631T3
(pl)
|
2005-10-28 |
2012-12-31 |
Astrazeneca Ab |
Pochodne 4-(3-aminopirazolo)pirymidyny do stosowania jako inhibitory kinazy tyrozynowej do leczenia raka
|
ES2372540T3
(es)
*
|
2005-11-01 |
2012-01-23 |
Array Biopharma, Inc. |
Activadores de glucocinasa.
|
US20070130203A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Ask Jeeves, Inc. |
Method and system to provide targeted advertising with search results
|
KR100728221B1
(ko)
*
|
2005-12-08 |
2007-06-13 |
한국전자통신연구원 |
터보부호 ofdm 시스템용 반복적 잔류 주파수 위상 보정장치 및 그 방법
|
US7572809B2
(en)
*
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
CN101437512A
(zh)
*
|
2006-01-27 |
2009-05-20 |
阿雷生物药品公司 |
葡萄糖激酶活化剂
|
US8658633B2
(en)
*
|
2006-02-16 |
2014-02-25 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating conditions of the eye
|
CN101437816B
(zh)
|
2006-03-24 |
2013-08-14 |
阿雷生物药品公司 |
作为葡萄糖激酶活性剂的2-氨基吡啶类似物
|
JP2009535393A
(ja)
*
|
2006-05-01 |
2009-10-01 |
ファイザー・プロダクツ・インク |
置換2−アミノ縮合複素環式化合物
|
US8246966B2
(en)
*
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
JP2008081492A
(ja)
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
EP2081431B1
(en)
|
2006-11-13 |
2013-01-16 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
EP2088863A2
(en)
|
2006-11-22 |
2009-08-19 |
University Of Georgia Research Foundation, Inc. |
Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
|
EP2089034A4
(en)
|
2006-12-05 |
2010-07-28 |
Intra Cellular Therapies Inc |
NEW USES
|
US8338455B2
(en)
|
2006-12-20 |
2012-12-25 |
Amgen Inc. |
Compounds and methods of use
|
PL2118099T3
(pl)
*
|
2007-02-13 |
2011-12-30 |
Ab Science |
Proces syntezy związków 2-aminotiazolu jako inhibitorów kinazy
|
EP2133095A4
(en)
|
2007-03-05 |
2012-09-26 |
Kyowa Hakko Kirin Co Ltd |
PHARMACEUTICAL COMPOSITION
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
CN101868459B
(zh)
*
|
2007-09-21 |
2013-12-18 |
阿雷生物药品公司 |
用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1,2,4-噻二唑衍生物
|
CN101821264A
(zh)
|
2007-10-09 |
2010-09-01 |
默克专利有限公司 |
可用作葡萄糖激酶激活剂的吡啶衍生物
|
ES2437595T3
(es)
|
2007-12-20 |
2014-01-13 |
Novartis Ag |
Derivados de tiazol usados como inhibidores de la PI 3 quinasa
|
WO2009130900A1
(ja)
*
|
2008-04-24 |
2009-10-29 |
日本曹達株式会社 |
オキシム誘導体、中間体化合物および植物病害防除剤
|
UA104147C2
(uk)
*
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
WO2010098839A1
(en)
|
2009-02-25 |
2010-09-02 |
Intra-Cellular Therapies, Inc. |
Pde 1 inhibitors for ophthalmic disorders
|
WO2010132127A1
(en)
|
2009-05-13 |
2010-11-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US8293753B2
(en)
*
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
DK2769737T3
(en)
|
2009-07-20 |
2017-07-24 |
Bristol Myers Squibb Co |
COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
|
EP2461673A4
(en)
|
2009-08-05 |
2013-08-07 |
Intra Cellular Therapies Inc |
NEW REGULATOR PROTEINS AND HEMMER
|
JP5513620B2
(ja)
*
|
2009-08-31 |
2014-06-04 |
ポステック・アカデミー‐インダストリー・ファウンデーション |
血管内皮細胞成長因子受容体の阻害によるTh17炎症疾患治療方法およびこのための薬学的組成物
|
RU2558797C2
(ru)
|
2009-10-20 |
2015-08-10 |
Нестек С.А. |
Способы выявления онкогенных слитых белков, основанные на анализе близкого взаимного расположения
|
KR100953511B1
(ko)
*
|
2009-12-28 |
2010-04-21 |
(주)지노믹트리 |
건선 진단용 키트 및 칩
|
AU2010343102B2
(en)
|
2009-12-29 |
2016-03-24 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
CA2816957A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
US8623889B2
(en)
|
2010-12-17 |
2014-01-07 |
Genentech, Inc. |
Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
|
EP2675494B1
(en)
|
2011-02-17 |
2016-05-18 |
Nestec S.A. |
Apparatus and method for isolating leukocytes and tumor cells by filtration
|
UA112539C2
(uk)
|
2011-03-03 |
2016-09-26 |
Новартіс Аг |
Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
|
US9255072B2
(en)
*
|
2011-03-04 |
2016-02-09 |
National Health Rsearch Institutes |
Pyrazole compounds and thiazole compounds as protein kinases inhibitors
|
RU2011122942A
(ru)
*
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
US8912224B2
(en)
|
2011-09-12 |
2014-12-16 |
Sanofi |
Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
|
KR101817925B1
(ko)
|
2011-09-12 |
2018-01-12 |
사노피 |
치환된 2-(크로만-6-일옥시)-티아졸 및 약제로서의 이의 용도
|
RS53748B1
(en)
|
2011-09-12 |
2015-06-30 |
Sanofi |
2- (CHROMAN-6-ILOXY) -THIAZOLES AND THEIR USE AS PHARMACEUTICAL PRODUCTS
|
SI2844282T1
(sl)
|
2012-05-04 |
2019-08-30 |
Pfizer Inc. |
S prostato povezani antigeni in na cepljenju osnovan imunoterapevtski režim zdravljenja
|
AU2013268400B2
(en)
|
2012-05-30 |
2017-07-13 |
Nippon Shinyaku Co., Ltd. |
Aromatic heterocyclic derivative and pharmaceutical
|
JP6549040B2
(ja)
|
2013-02-17 |
2019-07-24 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規使用
|
US9073936B2
(en)
|
2013-03-15 |
2015-07-07 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
EP3479825B1
(en)
|
2013-03-15 |
2021-02-17 |
Intra-Cellular Therapies, Inc. |
Pde1 inhibitors for use in the treatment and/or prevention of cns or pns diseases or disorders
|
CN103254184B
(zh)
*
|
2013-05-27 |
2015-03-18 |
湖南科技大学 |
5-取代-3-[5-羟基-4-吡喃酮-2-基-甲硫基]-4-氨基-1,2,4-三唑类化合物及其用途
|
CN103319467B
(zh)
*
|
2013-06-15 |
2015-10-14 |
湖南科技大学 |
一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途
|
TWI623551B
(zh)
|
2013-08-02 |
2018-05-11 |
輝瑞大藥廠 |
抗cxcr4抗體及抗體-藥物結合物
|
PL226024B1
(pl)
|
2013-10-23 |
2017-06-30 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną |
Zastosowanie N-[2-[4-(4-metoksyfenylo)-1,3-tiazol-2-ilo]etylo]- -2-okso-2,5,6,7-tetrahydrocyklopenta[b] pirydyno-3-karboksyamidu
|
US9884872B2
(en)
|
2014-06-20 |
2018-02-06 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
WO2016022893A1
(en)
|
2014-08-07 |
2016-02-11 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10059702B2
(en)
*
|
2014-09-08 |
2018-08-28 |
The Johns Hopkins University |
Inhibitors of LC3/ATG3 interaction and their use in the treatment of cancer
|
RU2711442C2
(ru)
|
2014-09-17 |
2020-01-17 |
Интра-Селлулар Терапиз, Инк. |
Соединения и способы
|
US10704104B2
(en)
|
2014-10-20 |
2020-07-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for screening a subject for a cancer
|
ES2764299T3
(es)
|
2014-12-09 |
2020-06-02 |
Inst Nat Sante Rech Med |
Anticuerpos monoclonales humanos contra AXL
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
WO2016160617A2
(en)
|
2015-03-27 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
LT3300500T
(lt)
|
2015-05-20 |
2020-05-25 |
Amgen Inc. |
Apj receptoriaus triazolo agonistai
|
CA2986083A1
(en)
*
|
2015-06-11 |
2016-12-15 |
Basilea Pharmaceutica International AG |
Efflux-pump inhibitors and therapeutic uses thereof
|
JP2018525029A
(ja)
|
2015-07-07 |
2018-09-06 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
ミオシン18aに対する特異性を有する抗体およびその使用
|
ES2955775T3
(es)
|
2015-08-27 |
2023-12-07 |
Inst Nat Sante Rech Med |
Métodos para predecir el tiempo de supervivencia de pacientes que padecen cáncer de pulmón
|
EP3347018B1
(en)
*
|
2015-09-09 |
2021-09-01 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
US20230183346A1
(en)
|
2016-02-26 |
2023-06-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity for btla and uses thereof
|
EP3436083A4
(en)
|
2016-03-28 |
2019-11-27 |
Intra-Cellular Therapies, Inc. |
NEW COMPOSITIONS AND METHODS
|
US9988369B2
(en)
|
2016-05-03 |
2018-06-05 |
Amgen Inc. |
Heterocyclic triazole compounds as agonists of the APJ receptor
|
BR112018074192A8
(pt)
|
2016-05-25 |
2022-11-22 |
Inst Nat Sante Rech Med |
Método para tratamento de um sujeito, método para produzir uma composição celular, composição de células, composição de vacina e kit
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
BR112019001693A2
(pt)
|
2016-07-29 |
2019-07-02 |
Ct Hospitalier Universitaire Toulouse |
anticorpos direcionados a macrófagos associados a tumores e seus usos
|
WO2018049417A1
(en)
|
2016-09-12 |
2018-03-15 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
EP3529262B1
(en)
|
2016-10-21 |
2021-07-21 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for promoting t cells response
|
US20190345500A1
(en)
|
2016-11-14 |
2019-11-14 |
|Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
US10689367B2
(en)
|
2016-11-16 |
2020-06-23 |
Amgen Inc. |
Triazole pyridyl compounds as agonists of the APJ receptor
|
US10736883B2
(en)
|
2016-11-16 |
2020-08-11 |
Amgen Inc. |
Triazole furan compounds as agonists of the APJ receptor
|
EP3541802A1
(en)
|
2016-11-16 |
2019-09-25 |
Amgen Inc. |
Alkyl substituted triazole compounds as agonists of the apj receptor
|
EP3541810B1
(en)
|
2016-11-16 |
2020-12-23 |
Amgen Inc. |
Triazole phenyl compounds as agonists of the apj receptor
|
WO2018097945A1
(en)
|
2016-11-16 |
2018-05-31 |
Amgen Inc. |
Heteroaryl-substituted triazoles as apj receptor agonists
|
WO2018093577A1
(en)
|
2016-11-16 |
2018-05-24 |
Amgen Inc. |
Cycloalkyl substituted triazole compounds as agonists of the apj receptor
|
EP3589654A1
(en)
|
2017-03-02 |
2020-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
EP3612225A1
(en)
*
|
2017-04-21 |
2020-02-26 |
Steven Hoffman |
Compositions and methods for treating retinopathy
|
EP3624798A1
(en)
|
2017-05-18 |
2020-03-25 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of mast cell diseases
|
WO2019072885A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
MAGNETIC NANOPARTICLES FOR THE TREATMENT OF CANCER
|
WO2019072888A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS OF PREDICTING THE THERAPEUTIC RESPONSE IN HEPATOCELLULAR CANCER
|
MA50509A
(fr)
|
2017-11-03 |
2021-06-02 |
Amgen Inc |
Agonistes de triazole fusionnés du récepteur apj
|
WO2019101956A1
(en)
|
2017-11-24 |
2019-05-31 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Methods and compositions for treating cancers
|
WO2019110750A1
(en)
|
2017-12-07 |
2019-06-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for screening a subject for a cancer
|
CN107868040A
(zh)
*
|
2017-12-21 |
2018-04-03 |
苏州艾缇克药物化学有限公司 |
一种2‑氨基吡啶‑4‑甲酸甲酯的合成方法
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
WO2019185683A1
(en)
|
2018-03-28 |
2019-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019194556A1
(ko)
*
|
2018-04-03 |
2019-10-10 |
영남대학교 산학협력단 |
신규한 6-헤테로아릴아미노-2,4,5-트라이메틸피리딘-3-올 화합물, 또는 이를 포함하는 염증성 장질환 및 자가면역 질환의 예방 또는 치료용 약학 조성물
|
WO2019197683A1
(en)
|
2018-04-13 |
2019-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
|
US11807624B2
(en)
|
2018-05-01 |
2023-11-07 |
Amgen Inc. |
Substituted pyrimidinones as agonists of the APJ receptor
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
CN113286589A
(zh)
|
2018-05-30 |
2021-08-20 |
大卫·马舒瓦尔 |
用于治疗癌症的方法和药物组合物
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
US20210236633A1
(en)
|
2018-08-06 |
2021-08-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers
|
KR102328682B1
(ko)
*
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
US20220047701A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
US20220098674A1
(en)
|
2019-02-13 |
2022-03-31 |
Inserm (Institut National De La Santé Et Dr La Recherch Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
CA3132219A1
(en)
|
2019-03-06 |
2020-09-10 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method to diagnose a cmmrd
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
JP2022538733A
(ja)
|
2019-05-20 |
2022-09-06 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
新規抗cd25抗体
|
US20220290244A1
(en)
|
2019-08-02 |
2022-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for screening a subject for a cancer
|
CN116348458A
(zh)
|
2019-08-14 |
2023-06-27 |
因赛特公司 |
作为cdk2抑制剂的咪唑基嘧啶基胺化合物
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
BR112022006977A2
(pt)
|
2019-10-11 |
2022-09-20 |
Incyte Corp |
Aminas bicíclicas como inibidores de cdk2
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
EP4149558A1
(en)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
EP4284420A1
(en)
|
2021-01-29 |
2023-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to diagnose msi cancer
|
US20220389104A1
(en)
|
2021-05-28 |
2022-12-08 |
Ose Immunotherapeutics |
Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
|
CN114230514A
(zh)
*
|
2021-11-26 |
2022-03-25 |
渭南瑞联制药有限责任公司 |
一种合成3-氟-2-氨基异烟腈的方法
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024061930A1
(en)
|
2022-09-22 |
2024-03-28 |
Institut National de la Santé et de la Recherche Médicale |
New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
|